SCHEMBL1959282

SCHEMBL1959282

O=C(CC1CCCC1)c1cc2cc(F)cnc2n1S(=O)(=O)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
NOD2 Q9HC29 1/20 0.35
NOD1 Q9Y239 1/20 0.35
CDK4 P11802 2/20 0.35
CCND1 P24385 2/20 0.35
HTR2A P28223 3/20 0.34
HTR2C P28335 3/20 0.34
KCNH2 Q12809 2/20 0.34
PDE5A O76074 1/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
FKBP1A P62942 1/20 0.34
PTGDR2 Q9Y5Y4 2/20 0.33
DRD2 P14416 1/20 0.33
HTR2B P41595 1/20 0.33
SIGMAR1 Q99720 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1959015 0.91 RIPK1 (0.38) ALDH1A1LMNAMAPTNOD2NOD1
SCHEMBL1962993 0.88 PDE5A (0.38) ALDH1A1LMNAMAPTNOD2NOD1
SCHEMBL1962404 0.87 ALDH1A1 (0.41) ALDH1A1LMNAMAPTPDE5APDE4A
SCHEMBL1958748 0.85 FKBP1A (0.38) LMNAMAPTFKBP1AHTR6
SCHEMBL1960226 0.85 FKBP1A (0.38) ALDH1A1LMNAMAPTFKBP1AHTR6
SCHEMBL1961946 0.85 ALDH1A1 (0.45) ALDH1A1LMNAMAPTPDE4BPTGDR2
SCHEMBL1958747 0.84 ALDH1A1 (0.38) ALDH1A1LMNACDK4CCND1BCHE
SCHEMBL1959207 0.84 AADAT (0.36) ALDH1A1LMNAMAPTFKBP1ABCHE
SCHEMBL1959963 0.82 ALDH1A1 (0.33) ALDH1A1LMNAMAPTNOD2NOD1
SCHEMBL1959066 0.81 ALDH1A1 (0.39) ALDH1A1LMNAMAPTNOD2NOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513103-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 ALDH1A1 769/4885LMNA 4695/4885MAPT 4347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.